Newsfeeds - Spark Newswire

1 minute read

FDA
News

AC Immune Awarded New Grants From MJFF, Target ALS Supporting Programs Targeting TDP-43

Today, 9:20 PM

The Michael J. Fox Foundation grant supports the development of AC Immune's first-in-class TDP-43 PET tracer program Target ALS Foundation grant supports collaboration between AC Immune and world-class

ACIU

1 minute read

News

AC Immune Granted U.S. Patent #11534484: Mimotopes of alpha-synuclein and vaccines thereof for the treatment of synucleinopathy

By Charles Gross

Today, 9:20 PM

https://www.scribd.com/document/616554009/ACIU-Patent

ACIU

5 minute read

Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday

By Lisa Levin

Today, 9:20 PM

Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday.

ACIU

5 minute read

Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday

By Lisa Levin

Today, 9:20 PM

Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial met its primary endpoint.

ABOS

4 minute read

Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

Today, 9:20 PM

Gainers

ABOS

2 minute read

AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 Into Late-Stage Development In Alzheimer’s Disease

By Bill Haddad

Today, 9:20 PM

AC Immune’s Tau PET tracer moves closer to becoming a next generation diagnostic for Alzheimer’s Disease (AD) AC Immune to receive a milestone payment from LMI for progress into late-stage product

ACIU

1 minute read

Detailed Data From Phase II Crenezumab Alzheimer’s Prevention Initiative Study In Autosomal Dominant Alzheimer’s Disease Presented At AAIC; Says Crenezumab Was Safe And Well Tolerated With No Cases Of ARIA-E Observed During The Up To Eight-Year Study

By Benzinga Newsdesk

Today, 9:20 PM

Crenezumab was safe and well tolerated with no cases of ARIA-E observed during the up to eight-year study As previously reported, numerical differences favoring crenezumab over placebo were confirmed across the

ACIU

3 minute read

AC Immune Announces Upcoming Presentations at the Alzheimer’s Association International Conference Jul. 31-Aug. 4

By Bill Haddad

Today, 9:20 PM

New data from the API ADAD Study to be presented in AAIC Focused Topic Session New Phase 2 results from investigator-sponsored trial of the Tau PET tracer PI-2620 in Alzheimer's

ACIU

1 minute read

SVB Leerink Maintains Outperform on AC Immune, Lowers Price Target to $10

By Benzinga Newsdesk

Today, 9:20 PM

SVB Leerink analyst Marc Goodman maintains AC Immune (NASDAQ:ACIU) with a Outperform and lowers the price target from $15 to $10.

ACIU

4 minute read

InflaRx Climbs More Than 40%, Here’s 58 Biggest Movers From Yesterday

By Lisa Levin

Today, 9:20 PM

Gainers Agile Therapeutics, Inc. (NASDAQ: AGRX) shares climbed 89.8% to close at $2.41 on Tuesday. Agile Therapeutics shares climbed over 10% on Monday amid the Supreme Court overturning Roe V Wade.

ACIU